Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-09-19

AUTHORS

Bilal H. Lashari, Yazhini Vallatharasu, Lakshmi Kolandra, Mohsin Hamid, Dipesh Uprety

ABSTRACT

Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable initial response to chemoradiation, relapse is invariable, and second-line regimens may be intolerable given the severity of side effects. For patients with tumors resistant to second-line regimens, no current standard regimens exist. Rovalpituzumab tesirine is a novel antibody-drug conjugate, targeting delta-like protein 3, fundamental in the downstream cellular signaling for proliferation and apoptosis. This drug is reported to have shown promise in pre-clinical and phase I trials. It appears effective in decreasing tumor burden and is reported to be well tolerated, albeit with a significant adverse effect profile. Currently, it is being studied as part of initial and subsequent line chemotherapeutic regimens; it remains to be seen if this is a viable option in the treatment of SCLC. This may add to the agents that can be used against SCLC, and help improve outcomes. More... »

PAGES

255-258

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40268-018-0247-7

DOI

http://dx.doi.org/10.1007/s40268-018-0247-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1107106147

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30232719


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzodiazepinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase I as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intracellular Signaling Peptides and Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Membrane Proteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Small Cell Lung Carcinoma", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lashari", 
        "givenName": "Bilal H.", 
        "id": "sg:person.07351701423.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07351701423.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI USA", 
          "id": "http://www.grid.ac/institutes/grid.413464.0", 
          "name": [
            "Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vallatharasu", 
        "givenName": "Yazhini", 
        "id": "sg:person.012755557601.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012755557601.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kolandra", 
        "givenName": "Lakshmi", 
        "id": "sg:person.07431100410.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07431100410.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamid", 
        "givenName": "Mohsin", 
        "id": "sg:person.010651642253.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010651642253.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI USA", 
          "id": "http://www.grid.ac/institutes/grid.413464.0", 
          "name": [
            "Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uprety", 
        "givenName": "Dipesh", 
        "id": "sg:person.0723720350.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723720350.17"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-09-19", 
    "datePublishedReg": "2018-09-19", 
    "description": "Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable initial response to chemoradiation, relapse is invariable, and second-line regimens may be intolerable given the severity of side effects. For patients with tumors resistant to second-line regimens, no current standard regimens exist. Rovalpituzumab tesirine is a novel antibody-drug conjugate, targeting delta-like protein 3, fundamental in the downstream cellular signaling for proliferation and apoptosis. This drug is reported to have shown promise in pre-clinical and phase I trials. It appears effective in decreasing tumor burden and is reported to be well tolerated, albeit with a significant adverse effect profile. Currently, it is being studied as part of initial and subsequent line chemotherapeutic regimens; it remains to be seen if this is a viable option in the treatment of SCLC. This may add to the agents that can be used against SCLC, and help improve outcomes.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40268-018-0247-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "small cell lung cancer", 
      "second-line regimens", 
      "lung cancer", 
      "treatment of SCLC", 
      "delta-like protein 3", 
      "significant adverse effect profile", 
      "novel antibody-drug conjugate", 
      "favorable initial response", 
      "current standard regimens", 
      "adverse effect profile", 
      "cell lung cancer", 
      "antibody-drug conjugates", 
      "standard regimens", 
      "smoking habits", 
      "rovalpituzumab tesirine", 
      "tumor burden", 
      "effect profile", 
      "chemotherapeutic regimens", 
      "side effects", 
      "regimens", 
      "protein 3", 
      "phase I", 
      "tumors", 
      "drug conjugates", 
      "initial response", 
      "global health", 
      "cancer", 
      "viable option", 
      "chemoradiation", 
      "tesirine", 
      "relapse", 
      "patients", 
      "epidemiology", 
      "incidence", 
      "conjugates", 
      "severity", 
      "antibodies", 
      "drugs", 
      "outcomes", 
      "treatment", 
      "burden", 
      "apoptosis", 
      "proliferation", 
      "health", 
      "options", 
      "years", 
      "agents", 
      "habits", 
      "response", 
      "cases", 
      "significant challenge", 
      "effect", 
      "recent years", 
      "changes", 
      "profile", 
      "promise", 
      "challenges", 
      "part", 
      "subsequent line chemotherapeutic regimens", 
      "line chemotherapeutic regimens", 
      "Novel DLL3-Targeting Antibody", 
      "DLL3-Targeting Antibody"
    ], 
    "name": "Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody\u2013Drug Conjugate", 
    "pagination": "255-258", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1107106147"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40268-018-0247-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30232719"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40268-018-0247-7", 
      "https://app.dimensions.ai/details/publication/pub.1107106147"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_763.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40268-018-0247-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0247-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0247-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0247-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0247-7'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      21 PREDICATES      100 URIs      92 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40268-018-0247-7 schema:about N1d2659116fe44961821170ad8515172d
2 N2a290e41fadc4f62a9b2bcb1bfd53138
3 N33fa12e418084ce7a5fef9ce6be13e8c
4 N3ab1472ceb7c484c9dd90238073ddb08
5 N64d59e8d616c4c73adb1be65101451ca
6 Na828604b172c4f8c8caa986acb6d0558
7 Nb519045d5c4741a08d1a69c5c30cedc8
8 Nbba718777b704f51ae5ccb11b0a73cfe
9 Nbe66788729f640df8fdba7a4a2a67b41
10 Nd19909e8f56842e8985815e6a0ebc049
11 Ndd66a28ab87546139c10ffe78109db91
12 Nef9f509fc7dd45ac98f6454368c39162
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author Ndbbfc8345ea54b4fb38192692e8043d8
16 schema:datePublished 2018-09-19
17 schema:datePublishedReg 2018-09-19
18 schema:description Small cell lung cancer (SCLC) comprises about 15% of all cases of lung cancer. In recent years, owing to a change in the epidemiology of smoking habits, the incidence of the tumor has decreased; however, it remains a significant challenge to global health. While the tumor has a favorable initial response to chemoradiation, relapse is invariable, and second-line regimens may be intolerable given the severity of side effects. For patients with tumors resistant to second-line regimens, no current standard regimens exist. Rovalpituzumab tesirine is a novel antibody-drug conjugate, targeting delta-like protein 3, fundamental in the downstream cellular signaling for proliferation and apoptosis. This drug is reported to have shown promise in pre-clinical and phase I trials. It appears effective in decreasing tumor burden and is reported to be well tolerated, albeit with a significant adverse effect profile. Currently, it is being studied as part of initial and subsequent line chemotherapeutic regimens; it remains to be seen if this is a viable option in the treatment of SCLC. This may add to the agents that can be used against SCLC, and help improve outcomes.
19 schema:genre article
20 schema:inLanguage en
21 schema:isAccessibleForFree true
22 schema:isPartOf N957178b14508403b9dec1c2838570629
23 Nba02d4920e184193a6a9ac4753cd0149
24 sg:journal.1020803
25 schema:keywords DLL3-Targeting Antibody
26 Novel DLL3-Targeting Antibody
27 adverse effect profile
28 agents
29 antibodies
30 antibody-drug conjugates
31 apoptosis
32 burden
33 cancer
34 cases
35 cell lung cancer
36 challenges
37 changes
38 chemoradiation
39 chemotherapeutic regimens
40 conjugates
41 current standard regimens
42 delta-like protein 3
43 drug conjugates
44 drugs
45 effect
46 effect profile
47 epidemiology
48 favorable initial response
49 global health
50 habits
51 health
52 incidence
53 initial response
54 line chemotherapeutic regimens
55 lung cancer
56 novel antibody-drug conjugate
57 options
58 outcomes
59 part
60 patients
61 phase I
62 profile
63 proliferation
64 promise
65 protein 3
66 recent years
67 regimens
68 relapse
69 response
70 rovalpituzumab tesirine
71 second-line regimens
72 severity
73 side effects
74 significant adverse effect profile
75 significant challenge
76 small cell lung cancer
77 smoking habits
78 standard regimens
79 subsequent line chemotherapeutic regimens
80 tesirine
81 treatment
82 treatment of SCLC
83 tumor burden
84 tumors
85 viable option
86 years
87 schema:name Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
88 schema:pagination 255-258
89 schema:productId N27cae1dc7b2d4ce1a3917117b50bc6d0
90 N590a9181054b42698c5c2f9e7787e250
91 Ne041057cdee344809e6765a6808660ce
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107106147
93 https://doi.org/10.1007/s40268-018-0247-7
94 schema:sdDatePublished 2021-12-01T19:40
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher N80404152751a46199d5bcca61fdfc4bf
97 schema:url https://doi.org/10.1007/s40268-018-0247-7
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N1d2659116fe44961821170ad8515172d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Intracellular Signaling Peptides and Proteins
103 rdf:type schema:DefinedTerm
104 N27cae1dc7b2d4ce1a3917117b50bc6d0 schema:name doi
105 schema:value 10.1007/s40268-018-0247-7
106 rdf:type schema:PropertyValue
107 N2a290e41fadc4f62a9b2bcb1bfd53138 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Benzodiazepinones
109 rdf:type schema:DefinedTerm
110 N2aa341c09f2e4606bc3a12d8565bfab4 rdf:first sg:person.010651642253.51
111 rdf:rest Nad130e8ddd2f44c8837afab112535916
112 N33fa12e418084ce7a5fef9ce6be13e8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Cell Proliferation
114 rdf:type schema:DefinedTerm
115 N3ab1472ceb7c484c9dd90238073ddb08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Antineoplastic Agents
117 rdf:type schema:DefinedTerm
118 N590a9181054b42698c5c2f9e7787e250 schema:name dimensions_id
119 schema:value pub.1107106147
120 rdf:type schema:PropertyValue
121 N64d59e8d616c4c73adb1be65101451ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Membrane Proteins
123 rdf:type schema:DefinedTerm
124 N6fc53d72fbbf4c0496dbc85ba7e2294b rdf:first sg:person.012755557601.44
125 rdf:rest Nf7d4fc88f8504c099f142021d6e59374
126 N80404152751a46199d5bcca61fdfc4bf schema:name Springer Nature - SN SciGraph project
127 rdf:type schema:Organization
128 N957178b14508403b9dec1c2838570629 schema:volumeNumber 18
129 rdf:type schema:PublicationVolume
130 Na828604b172c4f8c8caa986acb6d0558 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 Nad130e8ddd2f44c8837afab112535916 rdf:first sg:person.0723720350.17
134 rdf:rest rdf:nil
135 Nb519045d5c4741a08d1a69c5c30cedc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Apoptosis
137 rdf:type schema:DefinedTerm
138 Nba02d4920e184193a6a9ac4753cd0149 schema:issueNumber 4
139 rdf:type schema:PublicationIssue
140 Nbba718777b704f51ae5ccb11b0a73cfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Immunoconjugates
142 rdf:type schema:DefinedTerm
143 Nbe66788729f640df8fdba7a4a2a67b41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Small Cell Lung Carcinoma
145 rdf:type schema:DefinedTerm
146 Nd19909e8f56842e8985815e6a0ebc049 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Clinical Trials, Phase I as Topic
148 rdf:type schema:DefinedTerm
149 Ndbbfc8345ea54b4fb38192692e8043d8 rdf:first sg:person.07351701423.15
150 rdf:rest N6fc53d72fbbf4c0496dbc85ba7e2294b
151 Ndd66a28ab87546139c10ffe78109db91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Antibodies, Monoclonal, Humanized
153 rdf:type schema:DefinedTerm
154 Ne041057cdee344809e6765a6808660ce schema:name pubmed_id
155 schema:value 30232719
156 rdf:type schema:PropertyValue
157 Nef9f509fc7dd45ac98f6454368c39162 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Lung Neoplasms
159 rdf:type schema:DefinedTerm
160 Nf7d4fc88f8504c099f142021d6e59374 rdf:first sg:person.07431100410.37
161 rdf:rest N2aa341c09f2e4606bc3a12d8565bfab4
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
166 schema:name Oncology and Carcinogenesis
167 rdf:type schema:DefinedTerm
168 sg:journal.1020803 schema:issn 1174-5886
169 1179-6901
170 schema:name Drugs in R&D
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.010651642253.51 schema:affiliation grid-institutes:None
174 schema:familyName Hamid
175 schema:givenName Mohsin
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010651642253.51
177 rdf:type schema:Person
178 sg:person.012755557601.44 schema:affiliation grid-institutes:grid.413464.0
179 schema:familyName Vallatharasu
180 schema:givenName Yazhini
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012755557601.44
182 rdf:type schema:Person
183 sg:person.0723720350.17 schema:affiliation grid-institutes:grid.413464.0
184 schema:familyName Uprety
185 schema:givenName Dipesh
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723720350.17
187 rdf:type schema:Person
188 sg:person.07351701423.15 schema:affiliation grid-institutes:None
189 schema:familyName Lashari
190 schema:givenName Bilal H.
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07351701423.15
192 rdf:type schema:Person
193 sg:person.07431100410.37 schema:affiliation grid-institutes:None
194 schema:familyName Kolandra
195 schema:givenName Lakshmi
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07431100410.37
197 rdf:type schema:Person
198 grid-institutes:None schema:alternateName Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA
199 schema:name Department of Internal Medicine, Abington, Jefferson Health, Abington, PA USA
200 rdf:type schema:Organization
201 grid-institutes:grid.413464.0 schema:alternateName Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI USA
202 schema:name Department of Hematology and Medical Oncology, Gundersen Health System, La Crosse, WI USA
203 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...